deaths (OS)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
durvalumab plus tremelimumab vs. sorafenib 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0